Abstract
BackgroundCertain baseline factors in the BLISS trials were associated with high disease activity and identified as predictors of improved belimumab response.ObjectivesWe examined clinical effectiveness of belimumab 10 mg/kg plus standard...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
